Changes in N-glycosylation on specific
peptide sites of
serum proteins have been investigated as potential markers for diagnosis of
nonalcoholic steatohepatitis (NASH)-related HCC. To accomplish this work, a novel workflow involving broad-scale marker discovery in serum followed by targeted marker evaluation of these
glycopeptides were combined. The workflow involved an LC-Stepped HCD-
DDA-MS/MS method coupled with offline
peptide fractionation for large-scale identification of N-
glycopeptides directly from pooled serum samples (each n = 10) as well as differential determination of N-glycosylation changes between disease states. We then evaluated several potentially diagnostic N-
glycopeptides among 78 individual patient samples (40
cirrhosis, 28 early stage NASH HCC, and 10 late-stage NASH HCC) by LC-Stepped HCD-PRM-MS/MS to quantitatively analyze 65 targeted
glycopeptides from 7
glycoproteins. Of these targets, we found site-specific N-
glycopeptides n169GSLFAFR_HexNAc(4)Hex(5)NeuAc(2) and n242ISDGFDGIPDNVDAALALPAHSYSGR_HexNAc(5)Hex(6)Fuc(1)NeuAc(3) from VTNC were significantly increased comparing samples from patients with NASH
cirrhosis and NASH HCC (p < 0.05). When combining results of these 2
glycopeptides with AFP, the ROC curve analysis demonstrated the AUC value increased to 0.834 (95% CI, 0.748-0.921) and 0.847 (95% CI, 0.766-0.932), respectively, as compared to that of AFP alone (AUC = 0.791, 95% CI, 0.690-0.892). These 2
glycopeptides may serve as potential
biomarkers for early HCC diagnosis in patients with NASH related
cirrhosis.